그림 16. 피인용 수에 따른 특허 수의 분포
| ○ | 인플루엔자 기술에 속하는 특허 62546편 중 (2020-2024년 출판된 특허), 적어도 1회 이상 인용된 특허 수는 14510편(23.2%)임. |
| ○ | 인플루엔자 기술에 속하는 특허 중 피인용수가 높은 특허 리스트를 표 18 에 나타내었음. |
표 18. 고 피인용 특허 목록
| 번호 | 특허제목(미국특허번호) | 출원인 | 패밀리 특허번호 | 피인용 수 |
|---|---|---|---|---|
| 1 | Tissue thickness compensator configured to redistribute compressive forces (10624861) |
Ethicon LLC(US, PR, Guaynabo) | US 2022313619 A1 20221006; US 2020315983 A1 20201008; US 11559496 B2 20230124; US 2021259986 A1 20210826; US 2017367991 A1 20171228; US 10624861 B2 20200421; US 2021259987 A1 20210826; US 11850310 B2 20231226; US 2014205637 A1 20140724; US 9629814 B2 20170425 | 518 |
| 2 | Opioid overdose monitoring (10932729) |
MASIMO CORP(US, CA, Irvine) | WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 | 254 |
| 3 | Opioid overdose monitoring (10939878) |
MASIMO CORP(US, CA, Irvine) | WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 | 234 |
| 4 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10548857) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10548857 B2 20200204; US 2019008801 A1 20190110; US 2017304229 A1 20171026; US 10105327 B2 20181023 | 103 |
| 5 | Opioid overdose monitoring (11627919) |
MASIMO CORP(US, CA, Irvine) | WO 2019236759 A1 20191212; EP 3801207 A1 20210414; US 2021128078 A1 20210506; US 11564642 B2 20230131; KR 20210013641 A 20210204; KR 102241960 B1 20210421; CN 112512406 A 20210316; US 2019374173 A1 20191212; US 10932729 B2 20210302; US 2019374139 A1 20191212; US 10939878 B2 20210309; US 2019374713 A1 20191212; US 11627919 B2 20230418; JP 7174778 B2 20221117; JP 2021520958 A 20210826 | 100 |
| 6 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan (10596167) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2016361305 A1 20161215; US 2017360776 A1 20171221; US 10092561 B2 20181009; US 10596167 B2 20200324; US 2019015407 A1 20190117 | 100 |
| 7 | Bupropion and dextromethorphan for treating nicotine addiction (10688066) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2019290601 A1 20190926; US 10688066 B2 20200623 | 99 |
| 8 | Bupropion as a modulator of drug activity (10772850) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020230078 A1 20200723; US 10772850 B2 20200915 | 92 |
| 9 | Bupropion as a modulator of drug activity (10780064) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020261431 A1 20200820; US 2020246280 A1 20200806; US 10780064 B2 20200922 | 92 |
| 10 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10780066) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10080727 B2 20180925; US 2017304230 A1 20171026; US 2019008800 A1 20190110; US 10780066 B2 20200922 | 92 |
| 11 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10786469) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020093762 A1 20200326; US 10786469 B2 20200929 | 92 |
| 12 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10786496) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2018360823 A1 20181220; US 10786496 B2 20200929; US 2017281617 A1 20171005; US 10105361 B2 20181023 | 92 |
| 13 | Combination of dextromethorphan and bupropion for treating depression (10799497) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10799497 B2 20201013; US 2020147075 A1 20200514 | 92 |
| 14 | Bupropion and dextromethorphan for treating nicotine addiction (10813924) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10813924 B2 20201027; US 2020206217 A1 20200702 | 87 |
| 15 | Bupropion as a modulator of drug activity (10806710) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2016324807 A1 20161110; US 2017354619 A1 20171214; US 10058518 B2 20180828; US 10806710 B2 20201020; US 2019192450 A1 20190627 | 84 |
| 16 | Bupropion as a modulator of drug activity (10864209) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020230131 A1 20200723; US 10864209 B2 20201215 | 82 |
| 17 | Bupropion as a modulator of drug activity (10894046) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10894046 B2 20210119; US 2020215055 A1 20200709 | 81 |
| 18 | Bupropion as a modulator of drug activity (10894047) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10894047 B2 20210119; US 2020230130 A1 20200723 | 81 |
| 19 | Bupropion as a modulator of drug activity (10874664) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020230129 A1 20200723; US 10874664 B2 20201229 | 79 |
| 20 | Bupropion as a modulator of drug activity (10881657) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2019216798 A1 20190718; US 2020222388 A9 20200716; US 10881657 B2 20210105 | 79 |
| 21 | Bupropion as a modulator of drug activity (10874665) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10874665 B2 20201229; US 2020215058 A1 20200709 | 79 |
| 22 | Bupropion as a modulator of drug activity (10874663) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020222389 A1 20200716; US 10874663 B2 20201229 | 79 |
| 23 | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects (10881624) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2017360773 A1 20171221; US 10092560 B2 20181009; US 2016346276 A1 20161201; US 9763932 B2 20170919; US 10881624 B2 20210105; US 2019083426 A1 20190321 | 79 |
| 24 | Biosensor performance indicator for intraoral appliances (10639134) |
ALIGN TECHNOLOGY INC(US, CA, San Jose) | US 2018368961 A1 20181227; US 10639134 B2 20200505; WO 2019005808 A1 20190103; US 2023149143 A1 20230518; US 2020214817 A1 20200709; US 11576766 B2 20230214 | 75 |
| 25 | Bupropion as a modulator of drug activity (10945973) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020360310 A1 20201119; US 10945973 B2 20210316 | 75 |
| 26 | Bupropion as a modulator of drug activity (10933034) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020397724 A1 20201224; US 10933034 B2 20210302 | 74 |
| 27 | Bupropion as a modulator of drug activity (10925842) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2021000764 A1 20210107; US 10925842 B2 20210223 | 74 |
| 28 | Bupropion as a modulator of drug activity (10940124) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020405664 A1 20201231; US 10940124 B2 20210309 | 74 |
| 29 | Bupropion as a modulator of drug activity (10898453) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 2020297666 A1 20200924; US 10898453 B2 20210126 | 74 |
| 30 | Bupropion as a modulator of drug activity (10980800) |
ANTECIP BIOVENTURES II LLC(US, NY, New York) | US 10980800 B2 20210420; US 2021023075 A1 20210128 | 70 |
| 31 | Pharmaceutical compositions comprising meloxicam (10583144) |
AXSOME THERAPEUTICS, INC.(US, NY, New York) | US 10583144 B2 20200310; US 2020038408 A1 20200206 | 70 |
| 32 | Pharmaceutical compositions comprising meloxicam (10561664) |
AXSOME THERAPEUTICS, INC.(US, NY, New York) | US 2020030338 A1 20200130; US 10561664 B1 20200218; US 10702535 B2 20200707; US 2020155565 A1 20200521 | 70 |